412 related articles for article (PubMed ID: 30011918)
1. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects.
Lupo MG; Ferri N
J Cardiovasc Dev Dis; 2018 Jul; 5(3):. PubMed ID: 30011918
[TBL] [Abstract][Full Text] [Related]
2. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
[TBL] [Abstract][Full Text] [Related]
3. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
4. Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing.
Wang X; Musunuru K
JACC Basic Transl Sci; 2019 Oct; 4(6):755-762. PubMed ID: 31709322
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
6. Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment.
Lang W; Frishman WH
Cardiol Rev; 2019; 27(4):211-217. PubMed ID: 31008773
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
Kosmas CE; Bousvarou MD; Sourlas A; Papakonstantinou EJ; Peña Genao E; Echavarria Uceta R; Guzman E
Clin Pharmacol; 2022; 14():49-59. PubMed ID: 35873366
[TBL] [Abstract][Full Text] [Related]
9. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Dewey FE; Gusarova V; Dunbar RL; O'Dushlaine C; Schurmann C; Gottesman O; McCarthy S; Van Hout CV; Bruse S; Dansky HM; Leader JB; Murray MF; Ritchie MD; Kirchner HL; Habegger L; Lopez A; Penn J; Zhao A; Shao W; Stahl N; Murphy AJ; Hamon S; Bouzelmat A; Zhang R; Shumel B; Pordy R; Gipe D; Herman GA; Sheu WHH; Lee IT; Liang KW; Guo X; Rotter JI; Chen YI; Kraus WE; Shah SH; Damrauer S; Small A; Rader DJ; Wulff AB; Nordestgaard BG; Tybjærg-Hansen A; van den Hoek AM; Princen HMG; Ledbetter DH; Carey DJ; Overton JD; Reid JG; Sasiela WJ; Banerjee P; Shuldiner AR; Borecki IB; Teslovich TM; Yancopoulos GD; Mellis SJ; Gromada J; Baras A
N Engl J Med; 2017 Jul; 377(3):211-221. PubMed ID: 28538136
[TBL] [Abstract][Full Text] [Related]
10. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
11. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
Mohamed F; Mansfield BS; Raal FJ
Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
[TBL] [Abstract][Full Text] [Related]
12. New Biological Therapies for Low-Density Lipoprotein Cholesterol.
Gill PK; Hegele RA
Can J Cardiol; 2023 Dec; 39(12):1913-1930. PubMed ID: 37562541
[TBL] [Abstract][Full Text] [Related]
13. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
14. ANGPTL3 as therapeutic target.
Kersten S
Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
[TBL] [Abstract][Full Text] [Related]
15. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X; Peng DQ
Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
[TBL] [Abstract][Full Text] [Related]
16. Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.
Fazio S; Minnier J; Shapiro MD; Tsimikas S; Tarugi P; Averna MR; Arca M; Tavori H
J Clin Endocrinol Metab; 2017 Sep; 102(9):3340-3348. PubMed ID: 28633452
[TBL] [Abstract][Full Text] [Related]
17. Evinacumab to treat hypercholesterolemia.
Engler C; Ebenbichler C
Drugs Today (Barc); 2021 Oct; 57(10):607-619. PubMed ID: 34713869
[TBL] [Abstract][Full Text] [Related]
18. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212
[TBL] [Abstract][Full Text] [Related]
19. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH; Basu D; Goldberg IJ; Stitziel NO
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]